Dear Editor,
We read with interest the paper by Martineau and colleagues on intrahepatic cholestasis of pregnancy (ICP) published online on January 7 2014 (1) . We have also investigated pregnancy outcomes for women with ICP among 975,240 maternities in New South Wales (NSW), Australia. However unlike Martineau we did not find an increased risk of stillbirth.
Briefly, we conducted a cohort study of all births of at least 20 weeks gestation or 400g birthweight (n=975,240) Consistent with other studies (2-4) conducted in the era of active management of ICP but in contrast to
Martineau's case-control study (1), we found no increased risk of stillbirth in women diagnosed with ICP. However as we did not have data on serum bile acid levels, we could not determine ICP severity. It has recently been reported that amongst women with severe ICP (serum bile acid ≥40μmol/L) , there was a 3-fold increased risk of stillbirth despite active management (5). As there were only 3 stillbirths recorded in the 143 cases of ICP diagnosed in women in Martineau's study (1), compared to 11 stillbirths in 1870 ICP-affected maternities in the current study, it is possible that the apparent increased risk of stillbirth despite active management of ICP reflects a chance finding due to small numbers rather than a true increased risk of stillbirth. Alternatively, there may be a higher prevalence of severe ICP in this population. 
